次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

がん治療薬の世界市場2015-2025年:研究開発と業界動向

WORLD CANCER-TREATING DRUGS INDUSTRY AND MARKET: COMPANIES, THERAPIES, R&D AND FORECASTS 2015-2025

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年7月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文273ページになります。
商品コード:VGN432

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
がん治療薬の世界市場規模は2019年段階で1249億ドルに達し、2025年にかけて力強い市場成長が予測されます。当レポートでは、2015年から2025年に至るがん治療薬の世界市場予測、治療セグメント別市場予測(免疫療法、化学療法、標的治療、ホルモン療法)、主要40製品別・売上予測(Avastin/ Herceptin/ Rituxan/MabThera/ Gleevec/Glivecほか既存薬25ブランド、およびFarydak/ Ibranceほか新薬15ブランド)などの詳細予測データを掲載しています。また、がん部位別の治療薬の研究開発動向、リーディング企業8社動向、市場トレンド分析、専門家オピニオン取材などの調査情報を豊富に盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】VGN432_World Cancer-Treating Drugs Industry and Market Companies, Therapies, R&D and Forecasts 2015-2025 Cover.jpg
◆癌治療薬の世界市場予測2015-2025年

◆治療セグメント別市場予測2015-2025、および分析
・免疫療法
・化学療法
・標的治療
・ホルモン療法(ホルモン剤)

◆主要製品ブランド別売上予測2015-2025年
(※以下を含む主要25ブランドに加えて新薬15製品の予測データ掲載)
・Avastin
・Herceptin
・Rituxan/MabThera
・Gleevec/Glivec
・Revlimid
・Alimta
・Velcade
・Erbitux.
<※2014-15承認の新薬15製品、売上予測2015-25>
・Farydak
・Ibrance
・Lenvima
・Opdivo
・Unituxin
・Beleodaq
・Cyramza
・Imbruvica.
(※掲載の全製品名は詳細目次を参照ください)

◆主要11ヶ国、国別市場予測2015-2025
・米国
・日本
・ドイツ、フランス、英国、イタリア、スペイン
・ブラジル、ロシア、インド、中国

◆研究開発(R&D)パイプライン評価、トレンドと可能性
・乳がん
・前立腺がん
・肺がん
・腸がん
・子宮頸がん
・胃がん
・肝臓がん
・卵巣がん
・膀胱がん
・腎臓がん
・非ホジキンリンパ腫
・白血病

◆市場動向分析
・がんの有病率の増加傾向に伴う需要増加
・モノクローナル抗体(mAbs)、がんワクチン、非特異的免疫療法
・標的治療と分化誘導剤
・創薬における課題と機会、今後展望
・特許期限切れとジェネリック、バイオシミラーへの影響。激化する競合
・パーソナライズ医療への移行、バイオ医療技術
・ポイントオブケア、診断技術の進歩

◆リーディング製薬企業8社動向
・Roche
・Novartis
・Celgene
・Eli Lilly
・AstraZeneca
・Bristol-Myers Squibb
・Johnson & Johnson
・Merck & Co.

◆専門家オピニオンインタビュー2本:
・Dr Cesar M. Castro, Massachusetts General Hospital Cancer Center and Center for Systems Biology, Boston
・Dr Silvia Paddock, Senior Associate, Rose Li and Associates, Inc.

◆調査結論
(全273ページ、122個のデータ表、137個のチャート類)

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

WORLD CANCER-TREATING DRUGS INDUSTRY AND MARKET: COMPANIES, THERAPIES, R&D AND FORECASTS 2015-2025

Table of Contents

1. Report Overview

1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Cancer Treatments

2.1 The Physiology of Cancer – Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer – Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival – Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World – More Must Be Done
2.3 Treating Tumours – How Can We Fight Back?
2.3.1 Chemotherapy – The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy – A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents

3. The World Anti-Cancer Drugs Market, 2015-2025

3.1 Global Anti-Cancer Drugs Market Forecast, 2015-2025
3.2 The Domination of Immunotherapies in 2014
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2015-2025 – The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2015-2025
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2015-2025 – A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2015-2025

4. Leading National Markets, 2015-2025

4.1 Anti-Cancer Drugs – Leading Markets, 2014
4.2 The US Anti-Cancer Drugs Market, 2015-2025 – Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2014
4.2.2 The US Anti-Cancer Drugs Market Forecast – A Matured Approach
4.2.3 The Effect of Regulations on the US Market
4.3 The Japanese Anti-Cancer Drugs Market, 2015-2025 – Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2015-2025 – Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2015-2025 – Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2015-2025 – Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2015-2025 - Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2015-2025 – Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2015-2025 – Can it Reach its Potential?

5. The Top 25 Anti-Cancer Drugs: Revenue Forecasts, 2015-2025

5.1 Avastin (Roche) – The World Market Leader
5.1.1 Avastin Revenue, 2011-2014 – Mixed Growth
5.1.2 Avastin Revenue Forecast – Still No.1?
5.2 Herceptin (Roche) – The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2011-2014 – Still Rising
5.2.2 Herceptin Revenue Forecast – Generic Erosion
5.3 Rituxan/MabThera (Roche) – Slowing Growth
5.3.1 Rituxan Revenue, 2011-2014 – Still Strong
5.3.2 Rituxan Revenue Forecast – Heading for a Decline
5.4 Gleevec/Glivec (Novartis) – The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2011-2014
5.4.2 Glivec Revenue Forecast – What Does the Future Hold?
5.5 Revlimid (Celgene) – Celgene’s Top Revenue Generator
5.5.1 Revlimid Revenue, 2011-2014 – Still on the Rise
5.5.2 Revlimid Revenue Forecast – A Long Term Leader?
5.6 Alimta (Eli Lilly) – A Slow Decline?
5.6.1 Alimta Revenue, 2011-2014
5.6.2 Alimta Revenue Forecast – Revenue Erosion Looming
5.7 Velcade (J&J/Takeda) – Rising Steadily
5.7.1 Velcade Revenue, 2011-2014
5.7.2 Velcade Revenue Forecast – A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/Merck KGaA) – Facing Tough Competition
5.8.1 Erbitux Revenue, 2011-2014
5.8.2 Erbitux Revenue Forecast – No More Growth?
5.9 Gardasil (Merck & Co.) – The Rise of Prevention
5.9.1 Gardasil Revenue, 2011-2014
5.9.2 Gardasil Revenue Forecast – Still Growing Strong
5.10 Zytiga (Johnson & Johnson)
5.10.1 Zytiga Revenue, 2011-2014 – The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) – Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2011-2014 – The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast – A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2011-2014 – No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) – A Targeted Approach
5.13.1 Afinitor Revenue, 2011-2014 – Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2011-2014
5.14.2 Sprycel Revenue Forecast – How Long Will the Growth Last?
5.15 Tasigna (Novartis) – Moving Up
5.15.1 Tasigna Revenue, 2011-2014
5.15.2 Tasigna Revenue Forecast – A Multi-Billion Dollar Product?
5.16. Sutent (Pfizer)
5.16.1 Sutent Revenue, 2011-2014
5.16.2 Sutent Revenue Forecast – No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2011-2014 – The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast – A Promising Start
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2011-2014 – The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2011-2014
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) – Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2014
5.20.2 Yervoy Revenue Forecast – Will Sales Keep Growing?
5.21 Vidaza (Celgene) – What Growth Potential?
5.21.1 Vidaza Revenue, 2011-2014
5.21.2 Vidaza Revenue Forecast – Generic Impact?
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2011-2014
5.22.2 Treanda Revenue Forecast – Stalled Growth?
5.23 Temodar/Temodal (Merck & Co.) – Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2011-2014
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) – The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2011-2014
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) – Beginning the Climb
5.25.1 Abraxane Revenue, 2011-2014
5.25.2 Abraxane Revenue Forecast

6. Drugs Approved in 2014-2015: Potential Future Blockbusters

6.1 Approved Treatments in 2015
6.1.1 Farydak (panobinostat/Novartis)
6.1.2 Ibrance (palbociclib/Pfizer)
6.1.3 Lenvima (lenvatinib mesylate/Eisai)
6.1.4 Opdivo (nivolumab/Bristol-Myers Squibb)
6.1.5 Unituxin (dinutuximab/United Therapeutics)
6.2 Approved Treatments in 2014
6.2.1 Beleodaq (belinostat/Spectrum Pharmaceuticals)
6.2.2 Blincyto (blinatumomab/Amgen)
6.2.3 Cyramza (ramucirumab/Eli Lilly): A Breakthrough for Gastric Cancer?
6.2.4 Imbruvica (ibrutinib/Pharmacyclics)
6.2.5 Keytruda (pembrolizumab/Merck)
6.2.6 Lynparza (olaparib/AstraZeneca)
6.2.7 Zydelig (idelalisib/Gilead)
6.2.8 Zykadia (ceritinib/Novartis) - The Rise of Kinase Inhibitors
6.2.9 Tafinlar (Novartis) – A Partner for Mekinist
6.2.10 Kadycla (Roche) – A Future Star

7. Leading Companies for Cancer Treatments, 2014

7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche – Leader of the Pack
7.2.1 Oncology Pipeline – Investment in the Future
7.2.2 Roche’s Future Direction in Cancer Treatment
7.3 Novartis – Closing the Gap on Roche
7.3.1 Oncology R&D Pipeline – What’s the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene – A Pressing Need to Diversify?
7.4.1 Celgene’s Oncology R&D Pipeline – Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly – Reliant on Alimta
7.5.1 Oncology R&D Pipeline – What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca – Climbing Up the Ladder
7.6.1 Oncology R&D Pipeline – Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology R&D Pipeline – What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck &Co. – Prominent in Vaccines
7.8.1 Oncology R&D Pipeline – Greater Focus on Cancer
7.8.2 The Future Direction of Merck
7.9 Johnson & Johnson
7.9.1 Oncology J&J Pipeline – A Focus on Prostate Cancer Drugs

8. R&D Pipelines for Cancer Treatment

8.1 Breast Cancer Drugs under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Veliparib (Abbvie)
8.1.3 NeuVax (Galena Biopharma)
8.1.4 Entinostat (Syndax)
8.2 Prostate Cancer Drugs under Development
8.2.1 ODM-201 (Orion) – Jointly Developed with Bayer
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs under Development
8.3.1 RG7446 (Roche)
8.3.2 Nivolumab (Bristol-Myers Squibb)
8.3.3 MEDI4736 (AstraZeneca)
8.3.4 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 HA-Irinotecan (Alchemia)
8.5 Cervical Cancer Drugs under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck & Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.9 Bladder Cancer Drugs under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin’s Lymphoma Drugs under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs under Development
8.12.1 IMA901 (Immatics)
8.12.2 AGS-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck & Co.)

9. Qualitative Analysis of the Anti-Cancer Drug Market 2015-2025

9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment’s Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment

10. Research Interviews from Our Survey

10.1 Dr Cesar M. Castro, Massachusetts General Hospital Cancer Center and Center for Systems Biology, Boston
10.1.1 D3 Enables Point-of-care and Real Time Testing of Tumours
10.1.2 The Use of D3 to Detect Cancer
10.1.3 D3 – Speed, Ease of Use, Low Cost and Accurate
10.1.4 D3 – Possibility of Detecting Various Types of Cancer
10.1.5 Further Development and Refinement
10.2 Dr Silvia Paddock, Senior Associate, Rose Li and Associates, Inc.
10.2.1 PACE CII – Meeting the Needs of a Diverse Range of Stakeholders
10.2.2 PACE CII – Main Components
10.2.3 PACE CII – a Flexible Framework for Objective Assessments of Progress
10.2.4 Value of Cancer Treatments – Dynamic and Complex
10.2.5 Multiple Stakeholders - Shared Perspectives on Treatment Goals?
10.2.6 Free Access to Database and Tool

11. Conclusions of the Study

11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies – The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US – Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment – It’s Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks

List of Tables

Table 1.1 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2014-2019
Table 1.2 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2019-2025
Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2014
Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2014
Table 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.2 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2013-2014
Table 3.3 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue Forecast ($bn), CAGR (%) and Market Share (%), 2014, 2019 and 2025
Table 3.4 Global Immunotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.5 Global Chemotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.6 Global Targeted Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.7 Global Hormone Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.1 Anti-Cancer Drugs Market Revenue ($bn) and Market Share (%) by Leading Country, 2014, 2019, 2025
Table 4.2 Leading National Anti-Cancer Drugs Markets: Revenue Forecasts ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2015-2025
Table 4.3 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.4 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.5 EU5 Anti-Cancer Drugs Market Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.6 The BRIC Countries Anti-Cancer Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.7 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.8 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.9 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.10 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.1 Top 25 Anti-Cancer Drugs: Revenue ($bn) and Market Share (%), 2014
Table 5.2 Top 10 Anti-Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2014, 2019, 2025
Table 5.3 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025
Table 5.4 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025 (Contd.)
Table 5.5 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025 (Contd.)
Table 5.6 Avastin Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.7 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.8 Herceptin Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.9 Herceptin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.10 Rituxan/MabThera Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.11 Rituxan/MabThera Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.12 Glivec Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.13 Glivec Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.14 Revlimid Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.15 Revlimid Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.16 Alimta Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.17 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.18 Velcade Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.19 Velcade Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.20 Erbitux Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.21 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.22 Gardasil Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.23 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.24 Zytiga Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.25 Zytiga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.26 Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.27 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.28 Tarceva Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.29 Tarceva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.30 Afinitor Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.31 Afinitor Revenue Forecast ($bn), Annual Growth(%) and CAGR (%), 2015-2025
Table 5.32 Sprycel Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.33 Sprycel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.34 Tasigna Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.35 Tasigna Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.36 Sutent Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.37 Sutent: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.38 Nexavar Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.39 Nexavar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.40 Xgeva Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.41 Xgeva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.42 Zoladex Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.43 Zoladex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.44 Yervoy Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.45 Yervoy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.46 Vidaza Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.47 Vidaza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.48 Treanda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.49 Treanda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.50 Temodar Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.51 Temodar Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.52 Faslodex Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.53 Faslodex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.54 Abraxane Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.55 Abraxane: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.1 Farydak: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.2 Ibrance: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.3 Lenvima: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.4 Opdivo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.5 Unituxin: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.6 Beleodaq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.7 Blincyto: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.8 Cyramza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.9 Imbruvica: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.10 Keytruda: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.11 Lynparza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.12 Zydelig: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.13 Zykadia: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.14 Tafinlar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.15 Kadcyla: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 7.1 Anti-Cancer Drug Revenues ($bn) and Market Shares (%) of Leading Companies, 2013-2014
Table 7.2 Roche – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.3 Roche’s Anti-Cancer Drug Development Pipeline, 2014
Table 7.4 Novartis – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.5 Novartis’ Anti-Cancer Drug Pipeline, 2014
Table 7.6 Celgene – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.7 Celgene’s Anti-Cancer Drug Pipeline, 2014
Table 7.8 Eli Lilly – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.9 Eli Lilly’s Anti-Cancer Drug Pipeline, 2014
Table 7.10 AstraZeneca – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.11 AstraZeneca’s Anti-Cancer Drug Pipeline, 2014
Table 7.12 Bristol-Myers Squibb – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.13 Bristol-Myers Squibb Anti-Cancer Drug Pipeline, 2014
Table 7.14 Merck – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.15 Merck’s Anti-Cancer Drug Pipeline, 2014
Table 7.16 J&J – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.17 J&J’s Anti-Cancer Drug Pipeline, 2014
Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2014
Table 8.2 Breast Cancer Drugs under Development, 2014
Table 8.3 Prostate Cancer Drugs under Development, 2014
Table 8.4 Lung Cancer Drugs under Development, 2014
Table 8.5 Colorectal Cancer Drugs under Development, 2014
Table 8.6 Cervical Cancer Drugs under Development, 2014
Table 8.7 Stomach Cancer Drugs under Development, 2014
Table 8.8 Liver Cancer Drugs under Development, 2014
Table 8.9 Ovarian Cancer Drugs under Development, 2014
Table 8.10 Bladder Cancer Drugs under Development, 2014
Table 8.11 Non-Hodgkin’s Lymphoma Drugs under Development, 2014
Table 8.12 Leukaemia Drugs under Development, 2014
Table 8.13 Kidney Cancer Drugs under Development, 2014
Table 8.14 Pancreatic Cancer Drugs under Development, 2014
Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2015
Table 9.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2015

List of Figures

Figure 1.1 Anti-Cancer Market Segmentation, 2015
Figure 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 3.2 Global Anti-Cancer Drugs Market: Drivers and Restraints, 2015-2025
Figure 3.3 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2014
Figure 3.4 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2019
Figure 3.5 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2025
Figure 3.6 Global Immunotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Immunotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.8 Global Chemotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.9 Chemotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.10 Global Targeted Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.11 Targeted Therapy Market: Drivers and Restraints, 2015-2025
Figure 3.12 Global Hormone Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.13 Hormone Therapy Market: Drivers and Restraints, 2015-2025
Figure 4.1 Developed National Markets: Drivers and Restraints, 2015-2025
Figure 4.2 Emerging National Markets: Drivers and Restraints, 2015-2025
Figure 4.3 The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2014
Figure 4.4 The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2019
Figure 4.5 The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2025
Figure 4.6 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 4.7 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 4.8 The EU5 Anti-Cancer Drugs Markets: Revenue Forecast ($bn), 2015-2025
Figure 4.9 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2014
Figure 4.10 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2019
Figure 4.11 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2025
Figure 4.12 BRIC Countries Anti-Cancer Drugs Market Shares (%), 2014
Figure 4.13 BRIC Countries Anti-Cancer Drugs Market Shares (%), 2019
Figure 4.14 BRIC Countries Anti-Cancer Drugs Market Shares (%), 2025
Figure 4.15 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 4.16 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 4.17 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 4.18 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 5.1 Top 10 Anti-Cancer Drugs: Market Share (%), 2014
Figure 5.2 Top 10 Anti-Cancer Drugs: Market Share (%), 2019
Figure 5.3 Top 10 Anti-Cancer Drugs: Market Share (%), 2025
Figure 5.4 Avastin Revenue ($bn), 2011-2014
Figure 5.5 Avastin Revenue Forecast ($bn), 2015-2025
Figure 5.6 Avastin: Drivers and Restraints, 2015-2025
Figure 5.7 Herceptin Revenue ($bn), 2011-2014
Figure 5.8 Herceptin Revenue Forecast ($bn), 2015-2025
Figure 5.9 Herceptin: Drivers and Restraints, 2015-2025
Figure 5.10 Rituxan/MabThera Revenue ($bn), 2011-2014
Figure 5.11 Rituxan/MabThera Revenue Forecast ($bn), 2015-2025
Figure 5.12 Rituxan/MabThera: Drivers and Restraints, 2015-2025
Figure 5.13 Glivec Revenue ($bn), 2011-2014
Figure 5.14 Glivec Revenue Forecast ($bn), 2015-2025
Figure 5.15 Glivec: Drivers and Restraints, 2015-2025
Figure 5.16 Revlimid Revenue ($bn), 2011-2014
Figure 5.17 Revlimid Revenue Forecast ($bn), 2015-2025
Figure 5.18 Revlimid: Drivers and Restraints, 2015-2025
Figure 5.19 Alimta Revenue ($bn), 2011-2014
Figure 5.20 Alimta Revenue Forecast ($bn), 2015-2025
Figure 5.21 Alimta: Drivers and Restraints, 2015-2025
Figure 5.22 Velcade Revenue ($bn), 2011-2014
Figure 5.23 Velcade Revenue Forecast ($bn), 2015-2025
Figure 5.24 Velcade: Drivers and Restraints, 2015-2025
Figure 5.25 Erbitux Revenue ($bn), 2011-2014
Figure 5.26 Erbitux Revenue Forecast ($bn), 2015-2025
Figure 5.27 Erbitux: Drivers and Restraints, 2015-2025
Figure 5.28 Gardasil Revenue ($bn), 2011-2014
Figure 5.29 Gardasil Revenue Forecast ($bn), 2015-2025
Figure 5.30 Gardasil: Drivers and Restraints, 2015-2025
Figure 5.31 Zytiga Revenue ($bn), 2011-2014
Figure 5.32 Zytiga Revenue Forecast ($bn), 2015-2025
Figure 5.33 Zytiga: Drivers and Restraints, 2015-2025
Figure 5.34 Xeloda Revenue ($bn), 2011-2014
Figure 5.35 Xeloda Revenue Forecast ($bn), 2015-2025
Figure 5.36 Xeloda: Drivers and Restraints, 2015-2025
Figure 5.37 Tarceva Revenue ($bn), 2011-2014
Figure 5.38 Tarceva: Revenue Forecast ($bn), 2015-2025
Figure 5.39 Tarceva: Drivers and Restraints, 2015-2025
Figure 5.40 Afinitor Revenue ($bn), 2011-2014
Figure 5.41 Afinitor Revenue Forecast ($bn), 2015-2025
Figure 5.42 Afinitor: Drivers and Restraints, 2015-2025
Figure 5.43 Sprycel Revenue ($bn), 2011-2014
Figure 5.44 Sprycel Revenue Forecast ($bn), 2015-2025
Figure 5.45 Sprycel: Drivers and Restraints, 2015-2025
Figure 5.46 Tasigna Revenue ($bn), 2011-2014
Figure 5.47 Tasigna Revenue Forecast ($bn), 2015-2025
Figure 5.48 Tasigna: Drivers and Restraints, 2015-2025
Figure 5.49 Sutent Revenue ($bn), 2011-2014
Figure 5.50 Sutent: Revenue Forecast ($bn), 2015-2025
Figure 5.51 Sutent: Drivers and Restraints, 2015-2025
Figure 5.52 Nexavar Revenue ($bn), 2011-2014
Figure 5.53 Nexavar: Revenue Forecast ($bn), 2015-2025
Figure 5.54 Nexavar: Drivers and Restraints, 2015-2025
Figure 5.55 Xgeva Revenue ($bn), 2011-2014
Figure 5.56 Xgeva Revenue Forecast ($bn), 2015-2025
Figure 5.57 Xgeva: Drivers and Restraints, 2015-2025
Figure 5.58 Zoladex Revenue ($bn), 2011-2014
Figure 5.59 Zoladex: Revenue Forecast ($bn), 2015-2025
Figure 5.60 Zoladex: Drivers and Restraints, 2015-2025
Figure 5.61 Yervoy Revenue ($bn), 2011-2014
Figure 5.62 Yervoy Revenue Forecast ($bn), 2015-2025
Figure 5.63 Yervoy: Drivers and Restraints, 2015-2025
Figure 5.64 Vidaza Revenue ($bn), 2011-2014
Figure 5.65 Vidaza: Revenue Forecast ($bn), 2015-2025
Figure 5.66 Vidaza: Drivers and Restraints, 2015-2025
Figure 5.67 Treanda Revenue ($bn), 2011-2014
Figure 5.68 Treanda Revenue Forecast ($bn), 2015-2025
Figure 5.69 Treanda: Drivers and Restraints, 2015-2025
Figure 5.70 Temodar Revenue ($bn), 2011-2014
Figure 5.71 Temodar Revenue Forecast ($bn), 2015-2025
Figure 5.72 Temodar: Drivers and Restraints, 2015-2025
Figure 5.73 Faslodex Revenue ($bn), 2011-2014
Figure 5.74 Faslodex Revenue Forecast ($bn), 2015-2025
Figure 5.75 Faslodex: Drivers and Restraints, 2015-2025
Figure 5.76 Abraxane Revenue ($bn), 2011-2014
Figure 5.77 Abraxane: Revenue Forecast ($bn), 2015-2025
Figure 5.78 Abraxane: Drivers and Restraints, 2015-2025
Figure 6.1 Farydak: Revenue Forecast ($bn), 2015-2025
Figure 6.2 Ibrance: Revenue Forecast ($bn), 2015-2025
Figure 6.3 Lenvima: Revenue Forecast ($bn), 2015-2025
Figure 6.4 Opdivo: Revenue Forecast ($bn), 2015-2025
Figure 6.5 Unituxin: Revenue Forecast ($bn), 2015-2025
Figure 6.6 Beleodaq: Revenue Forecast ($bn), 2015-2025
Figure 6.7 Blincyto: Revenue Forecast ($bn), 2015-2025
Figure 6.8 Cyramza: Revenue Forecast ($bn), 2015-2025
Figure 6.9 Imbruvica: Revenue Forecast ($bn), 2015-2025
Figure 6.10 Keytruda: Revenue Forecast ($bn), 2015-2025
Figure 6.11 Lynparza: Revenue Forecast ($bn), 2015-2025
Figure 6.12 Zydelig: Revenue Forecast ($bn), 2015-2025
Figure 6.13 Zykadia: Revenue Forecast ($bn), 2015-2025
Figure 6.14 Tafinlar: Revenue Forecast ($bn), 2015-2025
Figure 6.15 Kadcyla: Revenue Forecast ($bn), 2015-2025
Figure 7.1 Anti-Cancer Drug Market Share (%) by Leading Company, 2013
Figure 7.2 Anti-Cancer Drugs Market Share (%) by Leading Company, 2014
Figure 7.3 Roche’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.4 Novartis’ Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.5 Celgene’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.6 Eli Lilly’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.7 AstraZeneca’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.8 Bristol-Myers Squibb’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.9 Merck’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.10 J&J Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2014
Figure 11.1 Top 25 Anti-Cancer Drugs: Revenues ($bn), 2014

掲載企業リスト

Companies Listed

AbbVie
Active Biotech
Advaxis
Alchemia
Allergan
American Cancer Society
Amgen
AmpImmune
Argos Therapeutics
ArQule
AstraZeneca
Barvarian Nordic
Bayer
Biothera
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Celator Pharmaceuticals
Celgene
Clovis Oncology
Cyclacel
Daiichi Sankyo
Dendreon
Dr. Reddy’s Laboratories
Eisai
Eli Lilly
EMA
Sanofi
EMD Serono
European Commission
FDA
Galena Biopharma
Gilead
GSK
Heat Biologics
Immatics Biotechnologies
Infinity Pharmaceuticals
Inovio Pharmaceuticals
Janssen
Japanese MHLW
Jennerex Biotherapeutics
Jiangsu Hengrui Medicine
Johnson & Johnson
Massachusetts General Hospital
MedImmune
Merck & Co.
Merck KGaA
Merrimack
National Cancer Institute
National Comprehensive Cancer Network
Newlink
Novartis
OncoGenex
Onyx
Orion
OSi Pharmaceuticals
Petrov Institute of Oncology
Pfizer
Pharmacyclics
Progen Pharmaceuticals
Puma Biotechnology
Roche
Rose Li and Associates
Spectrum Pharmaceuticals
Spirogen
Sun Pharma
Sunesis Pharmaceuticals
Syndax
Takeda
Telomedix
TESARO
Teva Pharmaceuticals
Tracon Pharma
Transgene
United Therapeutics
Vaccinogen
Viventia Biotech
Xbiotech

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。